Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413237 | 1.00 | CYP3A4 (1.00) | CYP3A4POLBTSHRMEN1KMT2A | |
| SCHEMBL9977927 | 0.93 | CYP3A4 (0.87) | CYP3A4POLBTSHRCYP2D6MAPT | |
| SCHEMBL16492255 | 0.91 | CYP3A4 (0.83) | CYP3A4POLBTSHRMEN1KMT2A | |
| SCHEMBL15019760 | 0.90 | CYP3A4 (0.82) | CYP3A4POLBTSHRMEN1KMT2A | |
| SCHEMBL16696055 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP2D6MAPTTNKSCACNA1G | |
| SCHEMBL15045878 | 0.88 | CYP3A4 (0.79) | CYP3A4TSHRMEN1KMT2ACYP2D6 | |
| SCHEMBL15257691 | 0.86 | CYP3A4 (0.75) | CYP3A4MEN1KMT2ACYP2D6MAPT | |
| SCHEMBL6245908 | 0.85 | CYP3A4 (0.74) | CYP3A4 | |
| SCHEMBL20769850 | 0.84 | CYP3A4 (0.73) | CYP3A4MEN1KMT2ACYP2D6MAPT | |
| SCHEMBL6243656 | 0.84 | CYP3A4 (0.73) | CYP3A4CYP2D6TNKSCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | claimed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | claimed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-105636936-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-04-05 | — | — | CN | claimed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | claimed |
| EP-3687543-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | claimed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | claimed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | claimed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | claimed |
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | claimed |
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | claimed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | claimed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | claimed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | claimed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| EP-1727550-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CYP3A4 3687/4885POLB 429/4885TSHR 4469/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | CYP3A4 1980/4885POLB 3263/4885TSHR 3359/4885 |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | CYP3A4 170/4885POLB 2357/4885TSHR 2549/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CYP3A4 3687/4885POLB 429/4885TSHR 4469/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | CYP3A4 3687/4885POLB 429/4885TSHR 4469/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CYP3A4 1980/4885POLB 3263/4885TSHR 3359/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | CYP3A4 3234/4885POLB 3210/4885TSHR 4229/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CYP3A4 1980/4885POLB 3263/4885TSHR 3359/4885 |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | CYP3A4 170/4885POLB 2357/4885TSHR 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.